Genetic analysis of UBQLN2-related neurodegenerative disease in ALS/FTD
Official title: Genetic analysis of UBQLN2-associated neurodegeneration in frontotemporal dementia
Funded at University of Wisconsin-Madison · NIH-11376726 · Data updated 2026-11-12
Researchers are studying how UBQLN2 gene changes contribute to ALS and frontotemporal dementia to better understand why these diseases develop.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | September 15, 2020 |
| Project end | March 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $545,241 |
| NIH project number | 2R01AG069483-03A1 |
| Project ID | NIH-11376726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with UBQLN2-related ALS/FTD or related UBQLN2 mutations, and healthy donors for iPSC controls.
✕Less likely to help
People without UBQLN2-related neurodegenerative disease are unlikely to directly benefit.
What this research studies
This project looks at how mutations in UBQLN2 cause neurodegeneration by combining fruit-fly genetics with human neuron models derived from patients’ cells. Using a fly-to-human approach, scientists identify pathways that make UBQLN2 toxicity worse and then test these findings in iPSC-derived motor neurons carrying ALS-associated UBQLN2 mutations. A special multi-mutation UBQLN2 variant, 4XALS, helps reveal disease mechanisms without simply overexpressing the protein. The goal is to map disease processes and point toward potential intervention strategies for ALS/FTD.
Why it matters
Potential benefit: If successful, the work could reveal targets to slow or halt UBQLN2-related neurodegeneration and inform future therapies for ALS/FTD patients.
How similar studies have gone: Previous studies using Drosophila models and patient-derived neurons have begun linking UBQLN2 dysfunction to disease pathways, supporting progress but needing validation in human cells.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Tibbetts, Randal Scot — University of Wisconsin-Madison
- Study coordinator: Tibbetts, Randal Scot
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Exploring how oxidative stress and ferroptosis affect frontotemporal dementia
A study using human iPSC-derived neurons from people with frontotemporal dementia to see how reactive oxygen species and a cell death process called ferroptosis relate to disease features.
-
Automated language analysis for Alzheimer’s disease and frontotemporal dementia in Latino and English speakers
A low-cost, automated speech and language analysis tool is being developed to help identify Alzheimer’s disease or frontotemporal dementia in Latino and English-speaking people.
-
Automated language analysis for Alzheimer’s and frontotemporal dementia across Latino and English-speaking groups
A low-cost, automated language study aims to help diagnose and understand Alzheimer’s and FTD in diverse Spanish- and English-speaking communities.
-
Automated language analysis to help diagnose Alzheimer’s and frontotemporal dementia in Latino and English speakers
A low-cost, computer-based method analyzes speech and language to help identify Alzheimer’s disease or frontotemporal dementia in Latino and English-speaking people.
-
Automated language analysis for Alzheimer's and frontotemporal dementia in Latino and English-speaking communities
A low-cost, computer-based language analysis method is being developed to help identify Alzheimer’s disease and frontotemporal dementia in Latino and English-speaking people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.